FI101538B - Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi - Google Patents

Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi

Info

Publication number
FI101538B
FI101538B FI932445A FI932445A FI101538B FI 101538 B FI101538 B FI 101538B FI 932445 A FI932445 A FI 932445A FI 932445 A FI932445 A FI 932445A FI 101538 B FI101538 B FI 101538B
Authority
FI
Finland
Prior art keywords
methyl
thieno
piperazinyl
preparation
therapeutically useful
Prior art date
Application number
FI932445A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932445L (fi
FI101538B1 (fi
FI932445A0 (fi
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI932445A0 publication Critical patent/FI932445A0/fi
Publication of FI932445L publication Critical patent/FI932445L/fi
Application granted granted Critical
Publication of FI101538B1 publication Critical patent/FI101538B1/fi
Publication of FI101538B publication Critical patent/FI101538B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI932445A 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi FI101538B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (4)

Publication Number Publication Date
FI932445A0 FI932445A0 (fi) 1993-05-28
FI932445L FI932445L (fi) 1993-11-30
FI101538B1 FI101538B1 (fi) 1998-07-15
FI101538B true FI101538B (fi) 1998-07-15

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932445A FI101538B (fi) 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi

Country Status (21)

Country Link
EP (1) EP0582368B1 (OSRAM)
JP (1) JP3219541B2 (OSRAM)
CN (1) CN1043994C (OSRAM)
AT (1) ATE198891T1 (OSRAM)
AU (1) AU668159B2 (OSRAM)
CA (1) CA2097016A1 (OSRAM)
CZ (1) CZ282783B6 (OSRAM)
DE (1) DE69329887T2 (OSRAM)
DK (1) DK0582368T3 (OSRAM)
ES (1) ES2153373T3 (OSRAM)
FI (1) FI101538B (OSRAM)
GR (1) GR3035587T3 (OSRAM)
HU (1) HU218278B (OSRAM)
IL (1) IL105827A (OSRAM)
MX (1) MX9303124A (OSRAM)
MY (1) MY109943A (OSRAM)
NO (1) NO305125B1 (OSRAM)
NZ (1) NZ247703A (OSRAM)
PT (1) PT582368E (OSRAM)
RU (1) RU2125574C1 (OSRAM)
TW (1) TW268005B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US6258807B1 (en) * 1996-03-25 2001-07-10 Eli Lilly And Company Method for treating pain
CA2250186A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
AU725556B2 (en) * 1996-03-25 2000-10-12 Eli Lilly And Company Method for treating pain
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CA2266444C (en) * 1996-09-23 2007-01-09 Eli Lilly And Company Olanzapine dihydrate d
CZ98899A3 (cs) * 1996-09-24 1999-12-15 Eli Lilly And Company Složení potahovaných částic
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
US9465041B2 (en) 2012-08-21 2016-10-11 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
JP6450314B2 (ja) 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
EP2888287A4 (en) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
ES2645433T3 (es) 2012-08-21 2017-12-05 Janssen Pharmaceutica, N.V. Haptenos de quetiapina para su uso en inmunoensayos
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
EP3492473B1 (en) * 2012-08-21 2025-07-30 Janssen Pharmaceutica NV Haptens of olanzapine
US9394354B2 (en) 2012-08-21 2016-07-19 Janssen Pharmaceutica Nv Haptens of paliperidone
US9751953B2 (en) 2012-08-21 2017-09-05 Janssen Pharmaceutica Nv Antibodies to risperidone haptens and use thereof
EP3581195B1 (en) 2012-08-21 2025-10-01 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
JP6131414B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールのハプテン及びイムノアッセイにおけるそれらの使用
AU2013305936B2 (en) 2012-08-21 2017-08-03 Saladax Biomedical Inc. Haptens of risperidone and paliperidone
AU2013305887B2 (en) 2012-08-21 2018-02-22 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
PL2888373T3 (pl) 2012-08-21 2018-08-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
AU2013305901B2 (en) 2012-08-21 2017-10-26 Saladax Biomedical Inc. Antibodies to olanzapine and use thereof
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
MA44067A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH569731A5 (OSRAM) * 1972-04-04 1975-11-28 Wander Ag Dr A
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
FI762646A7 (OSRAM) * 1975-09-24 1977-03-25 Sandoz Ag
CH624682A5 (OSRAM) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
MY109943A (en) 1997-10-31
DK0582368T3 (da) 2001-02-05
CZ102493A3 (en) 1993-12-15
DE69329887D1 (de) 2001-03-01
NZ247703A (en) 1995-07-26
MX9303124A (es) 1993-11-01
NO305125B1 (no) 1999-04-06
EP0582368A1 (en) 1994-02-09
AU668159B2 (en) 1996-04-26
FI932445L (fi) 1993-11-30
EP0582368B1 (en) 2001-01-24
DE69329887T2 (de) 2001-05-23
CN1085903A (zh) 1994-04-27
PT582368E (pt) 2001-05-31
FI101538B1 (fi) 1998-07-15
AU3980793A (en) 1993-12-02
ES2153373T3 (es) 2001-03-01
RU2125574C1 (ru) 1999-01-27
HU9301579D0 (en) 1993-09-28
NO931917D0 (no) 1993-05-26
NO931917L (no) 1993-11-30
CZ282783B6 (cs) 1997-10-15
JPH0687862A (ja) 1994-03-29
JP3219541B2 (ja) 2001-10-15
GR3035587T3 (en) 2001-06-29
TW268005B (OSRAM) 1996-01-11
FI932445A0 (fi) 1993-05-28
HU218278B (en) 2000-07-28
CA2097016A1 (en) 1993-11-30
HUT66180A (en) 1994-09-28
CN1043994C (zh) 1999-07-07
IL105827A (en) 1997-02-18
IL105827A0 (en) 1993-09-22
ATE198891T1 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
FI101538B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi
SE9703205D0 (sv) Ny kristallform av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno (2,3-b) (1,5)bensodiazepin och framställning därav
FR2511678B1 (fr) Derives de carbapeneme, leur procede de preparation et leur application en therapeutique
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
EP0255908A3 (en) 7-ûû3-(aminomethyl)-3-alkyl¨-1-pyrrolidinyl¨-quinoline-carboxylic acid-derivatives and pharmaceutical compositions containing them
AU636351B2 (en) N-heteroaryl-purin-6-amines, a process for their preparation and their use as medicaments
AU7124391A (en) Condensed thiazole compounds, their production and use
AU630575B2 (en) Benzodiazepine derivatives
HU895657D0 (en) Process for the preparation of mevalonolactones containing thienopyridine ring and pharmaceutical compositions containing such acitve ingredients
FI102178B (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,2,3,3a,8,8a-heksahydro-1, 3a,8-trimetyylipyrrolo£2,3-b|indol-5-yylijohdannaisten valmistamiseksi
FI92932B (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,2,3,3a,8,8a-heksahydro-1,3a,8-trimetyylipyrrolo/2,3-b/indol-5-yyli-karbonaattiestereiden valmistamiseksi
DK0594099T3 (da) Fremgangsmåde til rensning af rå clavulansyre
ES2051996T3 (es) Producto farmaceutico.
FI103885B (fi) Menetelmä terapeuttisesti aktiivisten 1-bentsyyli-4-fenyylipiperatsiinijohdannaisten valmistamiseksi ja välituotteina käyttökelpoisia yhdisteitä
FI104078B (fi) Menetelmä terapeuttisesti käyttökelpoisten (3-(1-piperatsinyyli)tieno£2,3-b|- ja -£2,3-c|pyridiinijohdannaisten valmistamiseksi
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof
CA2112980A1 (fr) Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone
KR937000511A (ko) 신규한 화합물
JO1870B1 (en) CO2 derivatives - pyridinyl benzimidazole innovative